BioLineRX
BLRX
29 hedge funds and large institutions have $1.49M invested in BioLineRX in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding
Funds holding: 29 → 29 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
30% less capital invested
Capital invested by funds: $2.12M → $1.49M (-$639K)
85% less call options, than puts
Call options by funds: $33K | Put options by funds: $223K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VFA
Values First Advisors
Gray,
Tennessee
|
+$190K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$94K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$39.5K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$29.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$232K |
| 2 |
VF
Virtu Financial
New York
|
-$48K |
| 3 |
JP Morgan Chase
New York
|
-$36.1K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$33.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$30.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $2K | +$2.51K | +50 | New |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $1.35K | -$16.5K | -328 | -92% |
|
|
TCM
28
Tradewinds Capital Management
Bellingham,
Washington
| $224 | – | – | – |
|
|
VF
29
Virtu Financial
New York
| – | -$48K | -759 | Closed |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$30.3K | -605 | Closed |
|
|
31
JP Morgan Chase
New York
| – | -$36.1K | -574 | Closed |
|
|
AMBIA
32
Allen Mooney & Barnes Investment Advisors
Thomasville,
Georgia
| – | -$23.6K | -375 | Closed |
|
BLRX Hedge Fund Activity: Q1 2024 in Review
29 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2024, worth a combined $1.49M — down 30% from $2.12M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BLRX positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Values First Advisors, adding an estimated $190K. The largest seller was Morgan Stanley, cutting an estimated $232K.
- 29 institutional investors held BioLineRX (BLRX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.49M of BioLineRX stock for Q1 2024, down 30% quarter-over-quarter.
- 6 funds opened new BioLineRX positions in Q1 2024 and 5 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q1 2024 was Values First Advisors, an estimated $190K added.
- The largest BioLineRX seller in Q1 2024 was Morgan Stanley, an estimated $232K sold.
Based on aggregated 13F filings for Q1 2024.